Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
详细信息 查看全文
- 作者：Rhiannon K Beckers ; Christina I Selinger ; Ricardo Vilain ; Jason Madore ; James S Wilmott ; Kate Harvey ; Anne Holliday ; Caroline L Cooper ; Elizabeth Robbins ; David Gillett ; Catherine W Kennedy ; Laurence Gluch ; Hugh Carmalt ; Cindy Mak ; Sanjay Warrier ; Harriet E Gee ; Charles Chan ; Anna McLean ; Emily Walker ; Catriona M McNeil ; Jane M Beith ; Alexander Swarbrick ; Richard A Scolyer and Sandra A O' ; Toole
- 刊名：Histopathology
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：69
- 期：1
- 页码：25-34
- 全文大小：971K
- ISSN：1365-2559
文摘
Triple-negative breast cancer (TNBC) patients generally have a poor outcome; there is a pressing need to identify more effective therapeutic strategies. Clinical trials targeting programmed death 1/programmed death ligand 1 (PD1/PDL1) in melanoma and non-small-cell lung cancer have reported high response rates, and tumoral PDL1 expression has been suggested as a potential biomarker to enrich for patient response to these treatments. There are only very limited data to date reporting the expression of PDL1 in TNBC.